Evolus
EOLS
156 hedge funds and large institutions have $557M invested in Evolus in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 70 increasing their positions, 38 reducing their positions, and 33 closing their positions.
96% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $2.3M
84% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 38
1.74% more ownership
Funds ownership: 80.26% → 82% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
5% less funds holding
Funds holding: 164 → 156 (-8)
19% less capital invested
Capital invested by funds: $691M → $557M (-$134M)
21% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 33
Top Buyers
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$12.2M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.4M |
| 3 |
BlackRock
New York
|
+$9.19M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$8.61M |
| 5 |
EP
Eversept Partners
New York
|
+$7.07M |
Top Sellers
EOLS Hedge Fund Activity: Q2 2024 in Review
156 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Evolus (EOLS) for Q2 2024, worth a combined $557M — down 19% from $691M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of EOLS and 26 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 70 added.
The largest buyer was Soleus Capital Management, adding an estimated $12.2M. The largest seller was Morgan Stanley, cutting an estimated $19.2M.
- 156 institutional investors held Evolus (EOLS) as of Q2 2024, down from 164 in Q1 2024.
- Funds reported $557M of Evolus stock for Q2 2024, down 19% quarter-over-quarter.
- 26 funds opened new Evolus positions in Q2 2024 and 33 closed out, a net change of -7 holders.
- The largest Evolus buyer in Q2 2024 was Soleus Capital Management, an estimated $12.2M added.
- The largest Evolus seller in Q2 2024 was Morgan Stanley, an estimated $19.2M sold.
Based on aggregated 13F filings for Q2 2024.